HOME >> BIOLOGY >> NEWS
Gene therapy a possibility for metachromatic leukodystrophy?

Metachromatic leukodystrophy (MLD) is an inherited disease that causes progressively more severe neurological defects that result in death early in life. Individuals with MLD have a genetic defect that means they lack a protein known as ARSA. There are currently no therapies for MLD, largely because the barrier between the blood supply and brain -- which tightly regulates the substances that can enter the brain -- provides an obstacle that has yet to be overcome. In a study appearing in the November issue of the Journal of Clinical Investigation, Alessandra Biffi and colleagues from the San Raffaele Scientific Institute in Italy, now show that the neurological defects in mice lacking ARSA can be corrected by treatment with hematopoietic stem progenitor cells (HSPCs) genetically modified to express high levels of ARSA. Importantly, ASRA was detected in the neurons of the treated mice and was derived from microglial cells, which differentiate from HSPCs. The successful correction of the protein defect in neurons and of the neurological defects led the authors to suggest that HSPC gene therapy might be efficacious for the treatment of individuals with MLD.


'"/>

Contact: Karen Honey
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
1-Nov-2006


Page: 1

Related biology news :

1. Testosterone replacement therapy: How safe for aging men?
2. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
3. Aggressive therapy best for certain AML patients
4. Under magnetic force, nanoparticles may deliver gene therapy
5. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
6. Stem cell therapy rescues motor neurons in ALS model
7. Study identifies new gene therapy tools for inherited blindness
8. Breast cancer and hormone therapy -- A looking-glass mirror?
9. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
10. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer
11. Scientists follow familiar TRAIL to new cancer therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/22/2018)... , ... December 21, 2018 , ... ... sponsored and hosted the Boston Healthcare Drinks event featuring Helen Chen, Greater China ... from China.” , The discussion was moderated by patent attorney David J. ...
(Date:12/19/2018)... ... 2018 , ... NDA Partners Chairman Carl Peck, MD, announced today that ... for Devices and Radiological Health (CDRH), has been appointed a Partner in the firm. ... she has more than 25 years of regulatory experience. In addition to her FDA ...
(Date:12/19/2018)... ... December 19, 2018 , ... OrthoSpace Ltd. (“OrthoSpace” or “the ... evaluating the use of novel surgical techniques, including the OrthoSpace InSpace™ balloon spacer, ... disabling condition for which there are historically few treatment options. The present study ...
Breaking Biology News(10 mins):
(Date:1/20/2019)... ... January 17, 2019 , ... TrakCel, the leading cell and ... Life Science Group (Quick Healthcare and QuickSTAT) today announce a partnership to offer ... and gene therapy industry to track products and manage the logistical processes of ...
(Date:1/15/2019)... ... 15, 2019 , ... With the U.S. Congress designating January as Cervical Health Awareness Month ... today announces tips to help reduce the risk of Cervical Cancer. , Cervical cancer ... is the #1 most common STD and an STI that almost half of ...
(Date:1/11/2019)... TORONTO (PRWEB) , ... January 11, 2019 , ... Drawing ... place on Tuesday, January 22, 2019 at 2:30pm EST will explore some of the ... and benefits of using one vendor vs. using multiple vendors, and find out how ...
(Date:1/10/2019)... (PRWEB) , ... January 08, ... ... Implant Co, (SAGICO), an innovative spinal implant company, announced today that SAGICO ... San Francisco, California. The annual J.P. Morgan Healthcare Conference is the ...
Breaking Biology Technology:
Cached News: